Vanda Pharmaceuticals Inc (VNDA)
4.88
+0.20
(+4.27%)
USD |
NASDAQ |
May 03, 16:00
5.05
+0.17
(+3.48%)
After-Hours: 20:00
Vanda Pharmaceuticals Accounts Receivable (Quarterly): 34.16M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 34.16M |
September 30, 2023 | 29.27M |
June 30, 2023 | 33.62M |
March 31, 2023 | 24.51M |
December 31, 2022 | 33.51M |
September 30, 2022 | 29.35M |
June 30, 2022 | 28.80M |
March 31, 2022 | 30.50M |
December 31, 2021 | 32.47M |
September 30, 2021 | 41.50M |
June 30, 2021 | 37.09M |
March 31, 2021 | 31.47M |
December 31, 2020 | 30.04M |
September 30, 2020 | 28.03M |
June 30, 2020 | 24.59M |
March 31, 2020 | 29.27M |
December 31, 2019 | 26.37M |
September 30, 2019 | 26.82M |
June 30, 2019 | 23.89M |
March 31, 2019 | 26.35M |
December 31, 2018 | 28.78M |
September 30, 2018 | 25.26M |
June 30, 2018 | 24.86M |
March 31, 2018 | 23.31M |
December 31, 2017 | 17.60M |
Date | Value |
---|---|
September 30, 2017 | 18.18M |
June 30, 2017 | 21.02M |
March 31, 2017 | 17.75M |
December 31, 2016 | 20.27M |
September 30, 2016 | 15.93M |
June 30, 2016 | 14.03M |
March 31, 2016 | 16.68M |
December 31, 2015 | 16.33M |
September 30, 2015 | 15.79M |
June 30, 2015 | 15.82M |
March 31, 2015 | 20.12M |
December 31, 2014 | 3.654M |
September 30, 2014 | 3.696M |
June 30, 2014 | 2.376M |
March 31, 2014 | 1.691M |
December 31, 2013 | 2.031M |
September 30, 2013 | 1.956M |
June 30, 2013 | 1.641M |
March 31, 2013 | 1.462M |
December 31, 2012 | 1.168M |
September 30, 2012 | 1.535M |
June 30, 2012 | 1.70M |
March 31, 2012 | 1.535M |
December 31, 2011 | 1.618M |
September 30, 2011 | 1.216M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
23.89M
Minimum
Jun 2019
41.50M
Maximum
Sep 2021
30.28M
Average
29.35M
Median
Sep 2022
Accounts Receivable (Quarterly) Benchmarks
ADMA Biologics Inc | 27.42M |
INVO Bioscience Inc | 0.1406M |
Johnson & Johnson | 14.95B |
Nektar Therapeutics | 1.205M |
Invivyd Inc | -- |